A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
NCT05498428
This study is recruiting at 14 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the anti-tumor activity and safety of amivantamab which will be administered as a co-formulation with recombinant human hyaluronidase PH20 (rHuPH20) (subcutaneous co-formulation [SC-CF]) in combination treatment (all cohorts except Cohort 4) and to characterize the safety of amivantamab SC-CF (Cohort 4).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-small-Cell Lung
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Janssen Research & Development, LLC
- Last updated on ClinicalTrials.gov
- September 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- University of California at San Diego · La Jolla, CA
- University of California Irvine · Orange, CA
- Stanford Cancer Institute · Stanford, CA
District of Columbia · 1
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital · Washington D.C., DC
Florida · 2
- Mount Sinai Medical Center · Miami Beach, FL
- AdventHealth · Orlando, FL
Kansas · 1
- University of Kansas Cancer Center · Westwood, KS
Maryland · 1
- Sidney Kimmel Cancer Center - Bayview Campus · Baltimore, MD
Massachusetts · 1
- Boston Medical Center · Boston, MA
Missouri · 1
- Washington University School Of Medicine · St Louis, MO
New Jersey · 2
- Hackensack University Medical Center · Hackensack, NJ
- Rutgers Cancer Institute of New Jersey · New Brunswick, NJ
Virginia · 1
- Virginia Cancer Specialists · Fairfax, VA
Washington · 1
- Swedish Cancer Institute · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.